Microarray testing in patients with systemic lupus erythematosus identifies a high prevalence of CpG DNA-binding antibodies | Lupus Science & Medicine

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Archive

Authors

About

Podcasts
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

PDF +
Supplementary
Material

Biomarker studies

Original research

Microarray testing in patients with systemic lupus erythematosus identifies a high prevalence of CpG DNA-binding antibodies

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Brunekreef T, Limper M, Melchers R, et al

Microarray testing in patients with systemic lupus erythematosus identifies a high prevalence of CpG DNA-binding antibodies

Lupus Science & Medicine 2021;8:e000531. doi: 10.1136/lupus-2021-000531